A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency

E-ISSN： 1757-4684|7|4|438-449

ISSN： 1757-4676

Source： EMBO Molecular Medicine, Vol.7, Iss.4, 2015-04, pp. : 438-449

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

EMBO Molecular Medicine, Vol. 7, Iss. 6, 2015-06 ,pp. : 831-847

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

EMBO Molecular Medicine, Vol. 7, Iss. 8, 2015-08 ,pp. : 1063-1076

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Conditions for Monetary Targeting in Slovenia

By Festic Mejra

Eastern European Economics, Vol. 40, Iss. 3, 2002-05 ,pp. : 69-89

M. E. Sharpe Inc

Access to resources Recommend Favorite

Inflation Targeting for Slovenia?

By Festić Mejra

Eastern European Economics, Vol. 41, Iss. 1, 2003-01 ,pp. : 79-98

M. E. Sharpe Inc

Access to resources Recommend Favorite

Canadian inflation targeting

Canadian Journal of Economics/Revue canadienne d'économique, Vol. 50, Iss. 5, 2017-12 ,pp. : 1556-1572

John Wiley & Sons Inc

Access to resources Recommend Favorite